A disproportionate number of the 37 million Americans that have kidney disease are of African American, Hispanic, Asian, or Native American descent. The use of race modifiers in the clinical algorithms used to detect and manage kidney disease have contributed to major kidney-health disparities among these ethnic minority groups.
NKF-ASN Task Force: Reassessing the Inclusion of Race in Diagnosing Kidney Diseases
achieve a consensus on replacing race-based equations for estimating glomerular filtration rate (eGFR);
assess the challenges brought on by implementing alternative methods; and
make recommendations as to the best approach for replacing current eGFR equations.
Based on input collected over 10 months from hundreds of patients, patient advocates, medical students, clinicians and scientists, the task force published its final report on September 23, 2021, recommending the "increased use of cystatin C combined with serum creatinine, as a confirmatory assessment of GFR or kidney function."
Cystatin C as a marker of kidney function
One key advantage of measuring cystatin C in addition to creatinine stems from the fact that cystatin C is less susceptible to factors that affect muscle mass (age, diet, sex, physical activity, etc.). Cystatin C is ubiquitously expressed through all nucleated cells. Individuals with similar kidney function can therefore be expected to have similar serum concentrations of cystatin C. This means that equations used for calculating GFR do not depend on an individual’s muscle mass or race.
Get in touch
If you and your colleagues would like to learn more about cystatin C and how you could incorporate this test into clinical workflows within your organization, please contact us via email@example.com, call 833-436-8426 (US customers) or fill out the form below: